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Aims Several randomized trials and a previous meta-analysis have shown signiﬁcant beneﬁts from Gp IIb-IIIa inhibitors,
especially abciximab. Recent randomized trials (BRAVE-3 and HORIZON trials) have shown no beneﬁts from adjunc-
tive Gp IIb-IIIa inhibitors on the top of clopidogrel administration. However, the relatively low mortality may have
hampered the conclusion of these recent trials. Thus, the aim of the current study was to perform an update
meta-analysis of randomized trials on adjunctive Gp IIb-IIIa inhibitors in primary angioplasty, and to evaluate by
meta-regression analysis, whether the results may be related to risk proﬁle.
Methods
and results
We obtained results from all randomized trials evaluating the beneﬁts of adjunctive Gp IIb-IIIa inhibitors among
STEMI patients undergoing primary angioplasty. The literature was scanned by formal searches of electronic data-
bases (MEDLINE and CENTRAL) from January 1990 to September 2008. The following key words were used: ran-
domized trial, myocardial infarction, reperfusion, primary angioplasty, Gp IIb-IIIa inhibitors, abciximab, tiroﬁban, and
eptiﬁbatide. Clinical endpoint was mortality at 30 days. Major bleeding complications were assessed as safety end-
point. No language restriction was applied. A total of 16 randomized trials were ﬁnally included in the meta-analysis,
involving 10 085 patients (5094 or 50.5% in the Gp IIb-IIIa inhibitors group and 4991 or 49.5% in the control group.
Gp IIb-IIIa inhibitors did not reduce 30 day mortality (2.8 vs. 2.9%, P ¼ 0.75) or re-infarction (1.5 vs. 1.9%, P ¼ 0.22),
but were associated with higher risk of major bleeding complications (4.1 vs. 2.7%, P ¼ 0.0004). However, we
observed a signiﬁcant relationship between patient’s risk proﬁle and beneﬁts from adjunctive Gp IIb-IIIa inhibitors
in terms of death (P ¼ 0.008) but not re-infarction (P ¼ 0.25).
Conclusion This meta-analysis shows a signiﬁcant relationship between beneﬁts in mortality from Gp IIb-IIIa inhibitors and
patient’s risk proﬁle. Thus, Gp IIb-IIIa inhibitors should be strongly considered among high-risk patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Primaryangioplastyhasbeenshowntoreducemortalitywhencom-
pared with thrombolysis, due to the ability to restore TIMI 3 ﬂow in
thevastmajorityofpatients.
1However,suboptimalreperfusionmay
be observed in a relatively large proportion of patients despite TIMI
3 ﬂow, mainly due to no-reﬂow phenomenon and distal emboliza-
tion.
2 Large interest has been focused on the adjunctive adminis-
tration of Gp IIb-IIIa inhibitors to improve perfusion and mortality.
A previous meta-analysis of randomized trials
3–16has shown signiﬁ-
cant beneﬁts in mortality and re-infarction.
17 However, these
beneﬁts have disappeared in recent large randomized trials
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18,19 conducted on the top of clo-
pidogrel administration. However, the relatively low mortality may
have hampered the conclusion of these recent trials. Thus, the
aim of the current study was to perform an update meta-analysis
of randomized trials on adjunctive Gp IIb-IIIa inhibitors in primary
angioplasty, and to evaluate by meta-regression analysis, whether
the results may be related to risk proﬁle.
Methods
Eligibility and search strategy
We obtained results from all randomized trials evaluating the beneﬁts
of adjunctive Gp IIb-IIIa inhibitors among STEMI patients undergoing
primary angioplasty. The literature was scanned by formal searches
of electronic databases (MEDLINE and CENTRAL) from January
1990 to September 2008. Furthermore, oral presentations and/or
expert slide presentations were included [searched on the TCT
(www.tctmd.com), EuroPCR (www.europcr.com), ACC (www.acc
.org), AHA (www.aha.org), and ESC (www.escardio.org) websites
from January 2002 to September 2008].The following key words
were used: randomized trial, myocardial infarction, reperfusion,
primary angioplasty, Gp IIb-IIIa inhibitors, abciximab, tiroﬁban, and
eptiﬁbatide.
Inclusion criteria were: (i) randomized treatment allocation; (ii) avail-
ability of complete clinical data. Exclusion criteria: (i) follow-up data in
less than 90% of patients; (ii) ongoing studies or irretrievable data. No
language restrictions were enforced.
Data extraction and validity assessment
Data were independently abstracted by two investigators. In case of
incomplete or unclear data, authors, where possible, were contacted.
Disagreements were resolved by consensus. Data were managed
according to the intention-to-treat principle.
Outcome
Primary and secondary endpoints were mortality and re-infarction at
30 days, respectively. Safety endpoint was the rate of major bleeding
complications.
Data analysis
Statistical analysis was performed using the Review Manager 4.27, SPSS
15.0 statistical package and Comprehensive Meta-analysis Version
2. Odds ratio (OR) and 95% conﬁdence intervals (95% CI) were
used as summary statistics. The pooled OR was calculated by using a
ﬁxed-effect model with the Mantel–Haenszel method. The DerSimo-
nian and Laird random effect model was additionally applied to calcu-
late pooled OR in case of signiﬁcant heterogeneity across studies.
Between-study heterogeneity was analysed by means of I
2 ¼ [(Q 2
df)/Q] 100%, where Q is the x
2 statistic, and df is its degrees of
freedom. The potential publication bias was examined by constructing
a ‘funnel plot’, in which the standard error (SE) of the ln OR was
plotted against the OR (30 day mortality).
The relationship between beneﬁts in mortality and risk proﬁle in
each study (study level variable) was evaluated by a weighted
random-effects meta-regression analysis regressing the log OR
against the control group event rate expressed as odds using the
inverse of the variance of the log OR as weight.
20
We additionally performed a weighted random-effects
meta-regression analysis regressing the log OR against the average
log event rate observed in experimental and control group combined,
using the inverse of the variance of the log OR as weight
20 and a
weighted random-effects meta-regression analysis regressing the log
odds in the experimental group against the log odds in the control
group, using the inverse of the variance of the log odds as weight.
21
Results are reported as beta coefﬁcients and two-sided P-values.
Similar analysis was conducted for 30 day re-infarction.
The study was performed in compliance with the Quality of Report-
ing of Meta-Analyses (QUORUM) guidelines.
22
Results
Eligible studies
Of the 859 potentially relevant articles initially screened, a total of
17 trials were initially identiﬁed
3–16,18,19,23,24 (Figure 1). One trial
4
was excluded because part of the ISAR trial.
5 Thus, a total of
16 randomized trials
3,5–16,18,19,23,24 were ﬁnally included in the
meta-analysis., involving 10 085 patients (5094 or 50.5% in the
Figure 1 Flow diagram of the systematic overview process. RCT, randomized controlled trials.
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Table 1 Characteristics of randomized trials included in the meta-analysis
Study Period N Study-drug design (number of patients) Primary endpoint Major bleeding complications
RAPPORT 1995–1997 483 Abciximab (n ¼ 241) vs. placebo (n ¼ 242) 6 month combined death, reMI, and TVR TIMI major bleeding
APE 1997–1998 59 Early (n ¼ 29) vs. no (n ¼ 30) abciximab Myocardial perfusion n.r.
ADMIRAL 1997–1998 300 Stenting þ abciximab (n ¼ 151) vs. placebo (n ¼ 149) 30 day combined death, reMI, urgent TVR TIMI major bleeding
CADILLAC 1997–1999 2082 Abciximab þ stent (n ¼ 524) or balloon (n ¼ 528), control þ stent
(n ¼ 512), or balloon (n ¼ 518)
6-month combined death, reMI, TVR, or
disabling stroke
Not deﬁned
Petronio et al. 1998–2000 89 Abciximab (n ¼ 44) vs. placebo (n ¼ 45) 6 month combined death, reMI, heart failure,
TLR
Substantial haemodynamic compromise
requiring treatment
ISAR-2 1997–1998 401 Stenting (n ¼ 200) vs. abciximab þ stenting (n ¼ 201) 6 month angiographic restenosis Intracranial haemorrhage, bleeding
requiring surgery or transfusion
ACE 2001–2002 400 Stenting (n ¼ 200) vs. abciximab þ stenting (n ¼ 200) Combined death, reMI stroke, and target
vessel
Stroke, bleeding requiring transfusion or
vascular repair
Zorman et al. 1998–2001 163 Early (n ¼ 56) vs. late (postangiography; n ¼ 56) abciximab vs. placebo
(n ¼ 51)
Early (60 min) ST-segment resolution Not deﬁned
Petronio et al. n.r 31 Abciximab (n ¼ 17) vs. control (n ¼ 14) Myocardial perfusion and functional recovery
at 30 days
TIMI major bleeding
Petronio et al. n.r 90 Abciximab (n ¼ 30) vs. adenosine (n ¼ 30) vs. control (n ¼ 30) LV remodelling GUSTO
Steen et al. 2000–2002 53 Tiroﬁban (n ¼ 24) vs. control (n ¼ 29) Myocardial perfusion n.r.
Ernst et al. 2002–2003 112 Abciximab (n ¼ 28) or tiroﬁban (n ¼ 29) or high-dose tiroﬁban (n ¼ 28) vs.
control (n ¼ 27)
Platelet aggregation inhibition Blood transfusion or surgery, intracranial
or peritoneal haemorrhage
Lee et al. n.r. 68 Abciximab (n ¼ 32) vs. control (n ¼ 36) Myocardial salvage n.r.
BRAVE-3 2004–2007 800 Abciximab (n ¼ 401) vs. placebo (n ¼ 399) Infarct size n.r.
HORIZONS-MI 2005–2007 3602 Glycoprotein IIb-IIIa inhibitors (n ¼ 1800) vs. bivalirudine (n ¼ 1802) Net clinical outcome and major bleeding
complications
TIMI major bleeding
On-TIME 2 2007–2008 984 Early high-dose tiroﬁban (n ¼ 491) vs. placebo (n ¼ 493) Residual cumulative ST-deviation TIMI major bleeding
ASSIST 2005–2008 400 Eptiﬁbatide (n ¼ 201) vs. placebo (n ¼ 199) Death, re-infarction, recurrent severe
ischaemia at 30 days
TIMI major bleeding
Abciximab dose: 0.25 mg/kg IV bolus followed by 12 h infusion at 0.125 mg kg
21 min
21. Eptiﬁbatide dose: 2 boluses of 180 mg/kg IV 10 min apart, then 2.0 mg kg
21 min
21 infusion. Tiroﬁban: 10 mg/kg bolus and 0.15 mg/kg/min infusion over
24 h. High-dose tiroﬁban: bolus of 25 mg/kg, followed by a 12 h infusion at 0.15 mg/kg/min.
n.r., not reported; reMI, re-infarction; TVR, target vessel revascularization; LV, left ventricle.
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7Gp IIb-IIIa inhibitors group and 4991 or 49.5% in the control
group). Characteristics of the included trials are shown in
Table 1. High-dose bolus (600 mg) of clopidogrel was admini-
strated in only three trials,
19,23,24 whereas in the Horizons trial
18
the dosage of bolus of clopidogrel was left to the discretion of
the treating physicians. In the study by Zorman et al.,
10 patients
were randomized to early vs. late administration (in the cath lab)
or no abciximab. In the Horizons trial,
18 the control group
received Bivalirudin as anticoagulation therapy instead of unfractio-
nated heparin.
Primary endpoint
As shown in Figure 2, overall Gp IIb-IIIa inhibitors did not reduce
30 day mortality [2.8 vs. 2.9%, OR (95% CI) ¼ 0.96 (0.76–1.22),
P ¼ 0.75, Phet ¼ 0.48, NNT ¼ 1000]. A trend in beneﬁts in mor-
tality was observed after the exclusion of the Horizons trial [2.6
vs. 3.3%, OR (95% CI)¼ 0.78 (0.58, 1.04), P ¼ 0.09, Phet ¼ 0.84;
NNT ¼ 143]. As shown in Figure 3, no publication biased was
observed.
As shown in Figure 4A, we observed a relationship between
patient’s risk proﬁle and mortality beneﬁts from adjunctive Gp
IIb-IIIa inhibitors (beta ¼ 214.12, P ¼ 0.008; without Horizons:
beta ¼ 210.31, P ¼ 0.08). The relationship was conﬁrmed when
beneﬁts were plotted against average events between experimen-
tal and control groups (beta ¼ 0.68, P ¼ 0.07; without Horizons:
beta ¼ 20.47, P ¼ 0.23) (Figure 4B). No signiﬁcant relationship
was observed between the odds of the experimental and
control groups (beta ¼ 0.23, P ¼ 0.21; without Horizons: beta ¼
0.40, P ¼ 0.06) (Figure 4C). In particular, the deviation of the
regression line, corresponding to the pooled treatment effect,
from the line of identity (Figure 4C) suggests heterogeneity and
further supports the relationship between risk proﬁle and mor-
tality beneﬁts.
Secondary endpoint
As shown in Figure 5, overall Gp IIb-IIIa inhibitors did not reduce
30 day re-infarction [1.5 vs. 1.9%, OR (95% CI) ¼ 0.82
(0.59–1.13), P ¼ 0.22, Phet ¼ 0.54; NNT ¼ 250]. Similar ﬁndings
were observed after the exclusion of the Horizons trial [1.3 vs.
Figure 2 Glycoprotein IIb-IIIa inhibitors and mortality beneﬁts at 30 day follow-up, with odds ratios and 95% conﬁdence intervals (CI). The
size of the data markers (squares) is approximately proportional to the statistical weight of each trial. *Without Horizon trial.
Figure 3 Funnel plot of all studies included in the
meta-analysis. Sample size of each study was plotted against the
odds ratio for 30 day mortality. No skewed distribution was
observed, suggesting no publication bias.
G. De Luca et al. 27081.9%, OR (95% CI) ¼ 0.70 (0.46–1.08), P ¼ 0.11, Phet ¼ 0.5;
NNT ¼ 167].
As shown in Figure 6A, no signiﬁcant relationship was observed
between the risk of re-infarction and beneﬁts from adjunctive
Gp IIb-IIIa inhibitors (beta ¼ 217.88, P ¼ 0.25; without Horizons:
beta ¼ 210.31, P ¼ 0.08). These data were conﬁrmed when the
beneﬁts were plotted against average events between experimen-
tal and control groups (beta ¼ 20.10, P ¼ 0.79; without Horizons:
beta ¼ 20.47, P ¼ 0.23) (Figure 6B). A signiﬁcant relationship was
observed between the odds of the experimental and control
groups (beta ¼ 0.55, P ¼ 0.03; without Horizons: beta ¼ 0.48,
P ¼ 0.12) (Figure 6C), with a minor deviation of the regression
line from the line of identity when compared with that observed
for mortality.
Safety endpoint
As shown in Figure 7, Gp IIb-IIIa inhibitors were associated with
higher risk of major bleeding complications [3.9 vs. 2.6%, OR
(95% CI) ¼ 1.50 (1.19–1.89), P ¼ 0.0005, Phet ¼ 0.85]. Similar
results were observed after exclusion of the Horizons trial [3.3
vs. 2.3%, OR (95% CI) ¼ 1.41 (1.04, 1.93), P ¼ 0.03, phet ¼ 0.8].
Discussion
The main ﬁnding of this meta-analysis is that among STEMI patients
undergoing primary angioplasty, there is a signiﬁcant relationship
between risk proﬁle and beneﬁts from adjunctive Gp IIb-IIIa
inhibitors in terms of mortality at 30 day follow-up.
Several randomized trials have shown that primary angioplasty is
superior to thrombolysis. However, despite primary angioplasty is
able to restore TIMI 3 ﬂow in the vast majority of patients, a rela-
tively large proportion of patients experience poor reperfusion.
2 In
the last years, growing interests have been focused on the role of
distal embolization as major determinant of poor reperfusion.
2 Gp
IIb-IIIa inhibitors are the most powerful class of antiplatelet thera-
pies, and their adjunctive beneﬁcial effects have been shown in
several randomized trials.
In the ACE trial,
13 a total of 400 STEMI patients were random-
ized to abciximab or placebo, all patients treated with stent implan-
tation. In this study, conducted without strict exclusion criteria,
and thus with mortality rates close to daily clinical practice, abcix-
imab was associated with a signiﬁcantly improved survival and
re-infarction. The beneﬁts in mortality have been conﬁrmed at
long-term follow-up.
25
Figure 4 (A) Weighted random-effects meta-regression analysis regressing the log odds ratio of mortality against the control group mortality
rate expressed as odds using the inverse of the variance of the log odds ratio as weight; this graph shows a relationship between risk proﬁle and
mortality beneﬁts from Gp IIb-IIIa inhibitors. (B) Weighted random-effects meta-regression analysis regressing the log odds ratio of mortality
against the average log mortality rate observed in experimental and control group combined, using the inverse of the variance of the log odds
ratio as weight; this graph shows a relationship between risk proﬁle and mortality beneﬁts from Gp IIb-IIIa inhibitors. (C) Weighted
random-effects meta-regression analysis regressing the log odds of mortality in the experimental group against the log odds of mortality in
the control group, using the inverse of the variance of the log odds as weight; this graph suggests heterogeneity and conﬁrm previous ﬁndings.
In fact, the line corresponding to the pooled treatment effect is not parallel to the line of identity (dashed line), as expected in case of homo-
geneous trials, but deviates from it.
Risk proﬁle and beneﬁts from Gp IIb-IIIa inhibitors 2709Several recent large randomized trials have been conducted to
explore the beneﬁts from adjunctive Gp IIb-IIIa inhibitors on the
top of clopidogrel administration, with contrasting results.
18,19,23,24
In the BRAVE-3 trial,
19 a total of 800 patients were randomized
to abciximab or placebo before angioplasty, on the top of 600 mg.
This study did not show beneﬁts either in the primary endpoint
(infarct size as estimated by scintigraphic techniques) or mortality
(2.5 vs. 3.2%). It must be remarked that even though the aim of the
study was to evaluate the impact of abciximab on infarct size, the
median ischaemia time was 4.5 h. It may be arguable whether any
adjunctive therapy in the late phase of ‘golden hours’ would
provide adjunctive beneﬁts in terms of infarct size. Furthermore,
the risk proﬁle was relatively low to evaluate the beneﬁts in
terms of clinical outcome.
In the large HORIZONS trial,
18 3602 STEMI patients were ran-
domized to heparin þ Gp IIb-IIIa inhibitors were compared with
bivalirudin. Patients received 300 or 600 mg clopidogrel loading
dose (the decision was left to the physician’s discretion).
Bivalirudin was surprisingly associated with a mortality reduction,
despite the signiﬁcantly higher rate of acute in-stent thrombosis.
As for the BRAVE-3 trial,
19 a relatively low-risk population has
been enrolled in this trial, that would have privileged bleeding
complications over thrombotic complications. In the recent
On-TIME-2 trial,
21 a total of 985 patients were randomized on
the top of 600 mg clopidogrel loading dose to early high-dose tir-
oﬁban vs. placebo (it was allowed periprocedural bail-out admin-
istration). Early tiroﬁban administration was associated with
beneﬁts in mortality (2.3 vs. 4%), even though the difference
was not statistically signiﬁcant due to the fact that the trials
was underpowered to detect a signiﬁcant reduction in mortality.
However, by pooling data of 414 open-label patients (patients
randomized in two Dutch centres as pilot phase) and 984 patients
included in the double-blind study (with a total of 1398 patients)
tiroﬁban administration was associated with reduced mortality
(2.2 vs. 4.1%, P ¼ 0.051).
In the current meta-analysis, we observed a signiﬁcant relation-
ship between risk proﬁle and beneﬁts in mortality, but not
re-infarction, from adjunctive Gp IIb-IIIa inhibitors. Thus, since clo-
pidogrel administration takes 3–4 h to reach the top of inhibition
of platelet aggregation,
26 Gp IIb-IIIa inhibitors should be considered
to rapidly inhibit platelets, with subsequent beneﬁts in mortality
according to the risk proﬁle. The use of risk scores, such as the
TIMI Risk Score,
27 should be strongly encouraged to identify a
higher risk population with thrombotic complications largely out-
weighing the risk of bleeding complications, and thus who may sub-
sequently beneﬁt in terms of mortality from aggressive
antithrombotic therapy.
Despite the negative results of the FINESSE trial,
28 early admin-
istration may certainly be encouraged due to the beneﬁts with
early administration observed in the Abciximab before Direct
Angioplasty and Stenting in Myocardial Infarction Regarding
Acute and Long-Term Follow-up (ADMIRAL) trial,
7 and in
several recent reports,
29–31 including On-TIME 2 trial.
23
Limitations
The use of a risk score based on individual patient’s data would
have overcome the limitation due to the use of mortality in
control group as marker of risk proﬁle.
19 In fact, the observed pro-
portions of events in the control groups of the trials, as a measure
of the underlying risk, may produce misleading results. This arises
Figure 5 Glycoprotein IIb-IIIa inhibitors and beneﬁts in re-infarction at 30 day follow-up, with odds ratios and 95% conﬁdence intervals (CI).
The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. *Without Horizon trial.
G. De Luca et al. 2710Figure 6 (A) Weighted random-effects meta-regression analysis regressing the log odds ratio of re-infarction against the control group
re-infarction rate expressed as odds using the inverse of the variance of the log odds ratio as weight; this graph shows no relationship
between risk proﬁle and beneﬁts in re-infarction from Gp IIb-IIIa inhibitors. (B) Weighted random-effects meta-regression analysis regressing
the log odds ratio of re-infarction against the average log re-infarction rate observed in experimental and control group combined, using the
inverse of the variance of the log odds ratio as weight; this graph shows no relationship between risk proﬁle and beneﬁts in re-infarction from
Gp IIb-IIIa inhibitors. (C) Weighted random-effects meta-regression analysis regressing the log odds of re-infarction in the experimental group
against the log odds of re-infarction in the control group, using the inverse of the variance of the log odds; the line corresponding to the pooled
treatment effect deviates of a minor extent from the line of identity (dashed line), when compared with that observed for mortality, conﬁrming
previous ﬁndings.
Figure 7 Glycoprotein IIb-IIIa inhibitors and major bleeding complications at 30 day follow-up, with odds ratios and 95% conﬁdence intervals
(CI). The size of the data markers (squares) is approximately proportional to the statistical weight of each trial. *Without Horizon trial.
Risk proﬁle and beneﬁts from Gp IIb-IIIa inhibitors 2711through a bias due to regression to the mean, especially observed
in meta-analyses which include some small trials or in which the
variability in the true underlying risks across trials is small. In
order to minimize this limitation and to conﬁrm initial ﬁndings,
we have performed additional analyses thought to be more appro-
priate such as the use of average proportion of events in the
control and treated groups as the measure of underlying risk or
to plot the proportion of events in the treated group against
that in the control group.
20
Even though high-dose clopidogrel bolus may obtain a quicker
and better platelet aggregation inhibition, the peak effect is still
observed after 3–4 h,
26 whereas Gp IIb-III inhibitors act very
rapidly. In fact, beneﬁts from Gp IIb-IIIa inhibitors were observed
in the On-TIME 2 trial
23 despite early administration of high-dose
600 mg clopidogrel, whereas in the BRAVE trial
19 clopidogrel was
administrated just before the procedure and thus less probably
affecting the results of the study. However, due to paucity of
data, no deﬁnite conclusion can be drawn on this issue. In addition,
we analysed short-term outcomes, whereas some Gp IIb-IIIa inhibi-
tor studies have demonstrated increased survival beneﬁt with
longer follow-up.
25 No uniform deﬁnition of major bleeding com-
plications was adopted in trials included in the current
meta-analysis. Finally, we could not exclude a clinical heterogeneity
between studies, due to different inclusion and exclusion criteria,
and study drugs.
Conclusions
This meta-analysis shows a signiﬁcant relationship between
beneﬁts in mortality from Gp IIb-IIIa inhibitors and patient’s risk
proﬁle. Thus, Gp IIb-IIIa inhibitors should be strongly considered
among high-risk patients.
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Primary cardiac T-cell lymphoma in a child
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A 10-year-old boy presented with a
12-week history of progressive breath-
lessness following a chest infection. He
had no history of pyrexia or night
sweats and no signiﬁcant weight loss.
On examination, the patient was well at
rest but breathless on minimal exertion.
He was slightly pale with palpable cervical
lymph nodes. His heart rate was
136 b.p.m. and blood pressure 107/75.
On auscultation, heart sounds were
mufﬂed with no audible murmurs, and
his chest was clear. Blood tests were
normal but a chest X-ray showed a
massive cardiomegaly (Panel A). An echo-
cardiogram showed a large pericardial
effusion which was compromising the
function of the heart. A pericardial drain
was inserted and the patient was unstable
throughout the procedure with bradycar-
dia requiring adrenaline boluses. Later the
same day, he had a cardiac arrest and car-
diopulmonary resuscitation (CPR) was
commenced. A sternotomy was performed to see if there was any reversible cause of cardiac arrest. The ﬁndings were of an inﬁltrat-
ing cardiac tumour surrounding the left and right ventricle. There was no residual effusion. In view of these ﬁndings and the prolonged
resuscitation, CPR was discontinued and the patient conﬁrmed dead.
At post-mortem there was a widespread malignant tumour involving the external surface of both ventricles (Panel B) with extension
into the roof of the left atrium (Panel C) and adjacent visceral and parietal pericardium. He also had widespread involvement of all
mediastinal lymph nodes. Histology conﬁrmed the diagnosis of a primary cardiac T-cell lymphoblastic lymphoma (Panel D).
Panel A. A chest X-ray (CXR) showing a massive cardiomegaly.
Panel B. Widespread malignant tumour involving the external surface of both ventricles.
Panel C. Widespread malignant tumour involving the external surface of both ventricles with extension into the roof of the left atrium.
Panel D. Histology showing inﬁltration of right and left ventricles by small malignant lymphoid cells. (Haematoxylin and eosin stain,
magniﬁcation  400). Inset: The cells stained positively for CD3.
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